Journal of Asthma最新文献

{"title":"Composite sleep patterns and the allergy-related composite outcome among American and Chinese older adults: exploration of depressive symptoms as a potential mediator.","authors":"Jiazhen Yao, Baozhen Dai, Jiacheng Zou, Lingqing Zhao","doi":"10.1080/02770903.2026.2751833","DOIUrl":"https://doi.org/10.1080/02770903.2026.2751833","url":null,"abstract":"<p><strong>Background: </strong>Sleep disturbances and depressive symptoms commonly co-occur in older adults, but their associations with heterogeneous allergy-related outcomes and the role of depressive symptoms remain unclear.</p><p><strong>Methods: </strong>We analyzed 1,562 participants aged ≥60 years from NHANES 2005-2006. A composite sleep pattern combined sleep duration, trouble sleeping, and diagnosed sleep disorders. The allergy-related composite outcome comprised elevated total immunoglobulin E and seven questionnaire-assessed disease or symptom outcomes. Survey-weighted logistic regression evaluated associations. Depressive symptoms were assessed with a modified 8-item Patient Health Questionnaire (PHQ-8), and statistical mediation examined indirect associations through its continuous score. We also conducted a complementary longitudinal analysis in 6,146 Chinese older adults from CHARLS.</p><p><strong>Results: </strong>Poor versus healthy sleep was associated with higher odds of the allergy-related composite outcome (OR 2.100; 95% CI 1.328-3.322), wheeze (OR 2.148; 95% CI 1.296-3.559), and sneeze (OR 1.636; 95% CI 1.135-2.357). The estimated indirect association through depressive symptoms represented 22.5% of the total association. In CHARLS, impaired sleep quality was associated with incident asthma (OR 1.689; 95% CI 1.254-2.275), and the corresponding indirect association through depressive symptoms represented 28.3% of the total association.</p><p><strong>Conclusion: </strong>Poor sleep was associated with heterogeneous allergy-related outcomes among US older adults, while CHARLS provided complementary longitudinal evidence for incident asthma. Depressive symptoms statistically accounted for part of the observed sleep-allergy association.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-15"},"PeriodicalIF":1.6,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective Observational Real-World Study to Assess the Effectiveness and Safety of Single-Inhaler Triple Therapy with Glycopyrrolate/Formoterol Fumarate/Budesonide in Patients with Uncontrolled Asthma.","authors":"Mohankumar Thekkinkattil, Subodh Katiyar, Bharat Gopal, Arnab Saha, Pralhad Prabhudesai","doi":"10.1080/02770903.2026.2751842","DOIUrl":"https://doi.org/10.1080/02770903.2026.2751842","url":null,"abstract":"<p><strong>Objectives: </strong>Individuals with asthma remain inadequately controlled despite treatment with inhaled corticosteroid and long-acting β₂-agonist (ICS/LABA) therapy. Single-inhaler triple therapy (SITT) combining ICS, LABA, and long-acting muscarinic antagonist (LAMA) offers a practical treatment escalation option. This study aims to assess the real-world effectiveness, safety, and adherence of SITT with budesonide/glycopyrrolate/formoterol fumarate in adults with uncontrolled asthma.</p><p><strong>Materials and methods: </strong>This multicentric, prospective, observational study was conducted across five centers in India. Adults with uncontrolled asthma on stable ICS/LABA therapy who were prescribed SITT as part of routine care were followed for 12 weeks. Changes in lung function, asthma control (ACT), and quality of life (Mini-AQLQ) were assessed. Medication adherence, adverse events, and asthma exacerbations were recorded.</p><p><strong>Results: </strong>Of 258 enrolled patients, 231 were included in the final analysis. Spirometry measurements showed notable improvements before and after bronchodilator use (all p < 0.001). These included higher MMEF values, suggesting improved small-airway function. Mean ACT scores improved from 14.29 at baseline to 18.49 at follow-up. Mini-AQLQ scores also improved over 12 weeks, indicating better patient-reported quality of life. Medication adherence was high, and no asthma exacerbations, adverse events, or serious adverse events were reported during follow-up.</p><p><strong>Conclusion: </strong>In routine practice, SITT BGF was associated with short-term improvements in lung function, asthma control, and QoL in adults with uncontrolled asthma. The mean ACT improved to partially controlled range at 12 weeks. Results suggest short-term effectiveness and tolerability, but longer-term and comparative studies are needed.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-12"},"PeriodicalIF":1.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/02770903.2026.2747428","DOIUrl":"https://doi.org/10.1080/02770903.2026.2747428","url":null,"abstract":"","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1"},"PeriodicalIF":1.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149194110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of mepolizumab in patients switching from prior biologic treatments for severe asthma: a post hoc analysis of the NUCALA effectiveness study (NEST).","authors":"Alejandra Galeano Mesa, Riyad Omar Al-Lehebi, Sevim Bavbek, Nasser Al Busaidi, Bassam Mahboub, Venkata Nagarjuna Maturu, Tayseer Ibrahim, Emilio Feres, Elizabeth Garcia, Gur Levy, Seema Haider, Saeed Noibi, Mona Al-Ahmad","doi":"10.1080/02770903.2026.2730876","DOIUrl":"10.1080/02770903.2026.2730876","url":null,"abstract":"<p><strong>Introduction: </strong>Biologic therapy is recommended for patients with severe asthma that remains uncontrolled despite receiving optimal therapy. This post hoc analysis of the Nucala Effectiveness Study (NEST) assessed real-world effectiveness of mepolizumab in biologic-experienced patients with severe asthma.</p><p><strong>Methods: </strong>For this post hoc analysis of NEST (a multi-country, bi-directional, observational cohort study in Chile, Colombia, India, Kuwait, Oman, Qatar, Saudi Arabia, Türkiye and United Arab Emirates), data from biologic-experienced patients were included. The primary outcome was comparison of clinically significant exacerbation (CSE) incidence rates 12 months pre and post mepolizumab initiation. Secondary outcomes included changes in oral corticosteroid (OCS) use and Asthma Control Test (ACT) scores.</p><p><strong>Results: </strong>Data from 174 patients were included; 94.8% received omalizumab previously and 84.8% had discontinued use due to lack of treatment efficacy. Incidence rate ratio (95% confidence interval) was 0.26 (0.18-0.36; 74.0% reduction in CSEs post initiation). Of 170 patients, OCS use reduced from 60.0% (<i>n</i> = 102) to 23.5% (<i>n</i> = 40); 39/102 (38.2%) patients continued OCS use post mepolizumab initiation. Among OCS users, mean (standard deviation [SD]) OCS dose reduced from 20.8 (17.3) to 6.7 (15.3) mg/day post initiation. Mean (SD) ACT scores improved from 14.0 (5.4; <i>n</i> = 139) to 19.5 (5.2; <i>n</i> = 140) post initiation; of 125 patients, 66.4% achieved <i>a</i> ≥ 3-point increase in ACT score.</p><p><strong>Conclusion: </strong>Mepolizumab treatment led to reduced CSEs and OCS use, and improved ACT scores in biologic-experienced patients with severe asthma. These findings indicate the importance of a patient-centred approach regarding biologic treatment.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-13"},"PeriodicalIF":1.6,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148989731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic cough in adults: a contemporary review of cough hypersensitivity syndrome and clinical management.","authors":"Dianelys Perla Sierra, Bibi Waleema Bacchus-Ali, Saleem N Hamilah, Haroon Al-Shaor","doi":"10.1080/02770903.2026.2738099","DOIUrl":"10.1080/02770903.2026.2738099","url":null,"abstract":"<p><strong>Objective: </strong>To synthesize evidence on the causes, assessment, and management of adult chronic cough, emphasizing cough hypersensitivity, treatable traits, and a mechanism-based clinical approach.</p><p><strong>Data sources: </strong>PubMed/MEDLINE and the Cochrane Library were searched for English-language literature published from January 2015 through September 2026, supplemented by reference-list review and selected earlier seminal studies.</p><p><strong>Study selections: </strong>Priority was given to international guidelines, consensus statements, systematic reviews, meta-analyses, randomized trials, and major clinical reviews addressing chronic cough, refractory or unexplained cough, cough hypersensitivity, laryngeal and reflux-associated disorders, treatable traits, and emerging antitussive therapies.</p><p><strong>Results: </strong>Chronic cough commonly reflects overlapping respiratory, upper-airway or laryngeal, reflux-associated, medication-related, and neural mechanisms. Cough hypersensitivity is increasingly recognized as an important feature, particularly in refractory or unexplained chronic cough, but should not be assumed to explain every presentation. Inducible laryngeal obstruction is appropriately considered within upper-airway and laryngeal disorders. Gastroesophageal reflux disease and laryngopharyngeal reflux may overlap in patients with cough, although causal attribution is often difficult and the two conditions should not be regarded as interchangeable diagnoses. Initial evaluation should include structured history taking, physical examination, identification of red flags, chest radiography, spirometry, and targeted assessment of treatable traits. Persistent symptoms despite appropriate management may indicate refractory or unexplained chronic cough associated with ongoing neural sensitization.</p><p><strong>Conclusion: </strong>Current evidence supports an individualized, mechanism-based approach that prioritizes identification and treatment of relevant diseases and treatable traits while recognizing cough hypersensitivity as a potential therapeutic target. Emerging peripheral neural therapies may broaden future treatment options for refractory chronic cough.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-12"},"PeriodicalIF":1.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare providers' prescription practices for spacer devices and mask sizes in pediatric asthma care.","authors":"Marina Reznik, Witness Chirinda","doi":"10.1080/02770903.2026.2734968","DOIUrl":"10.1080/02770903.2026.2734968","url":null,"abstract":"<p><strong>Background: </strong>Asthma guidelines recommend that children use a valve-holding chamber or spacer with inhalers for optimal delivery of asthma medications. Spacers with correct-fitting face masks should be used to deliver the full dose of medication.</p><p><strong>Objective: </strong>To evaluate healthcare providers' prescription practices regarding spacer devices for children, focusing on factors influencing mask size specification.</p><p><strong>Methods: </strong>We conducted a cross-sectional survey with pediatric and family medicine providers across 18 Bronx, NY clinics. The survey assessed providers' preferences for prescribing spacers, frequency of mask size specification, barriers to prescribing and possible solutions. Data were analyzed using descriptive statistics, chi-square tests, and multivariable logistic regression.</p><p><strong>Results: </strong>149 providers participated (response rate: 71.0%). Providers who assessed inhaler-spacer technique during visits were more likely to specify mask sizes than providers who do not assess the technique (54.0% vs 33.3%, <i>p</i> = 0.017). Pediatricians specified mask sizes more often than family providers (52.5% vs. 21.4%, <i>p</i> = 0.003). Providers who frequently saw children with asthma had significantly higher odds of specifying mask sizes (OR = 2.64, 95% CI: 1.20-5.98, <i>p</i> = 0.017), as did those who reported patients bringing spacers to visits (OR = 2.59, 95% CI: 1.26-5.47, <i>p</i> = 0.011). Barriers cited included insurance coverage issues, pharmacies not having spacers with masks in stock, and challenges in ordering spacers via Electronic Health Records. Suggested solutions included having models of spacers in the office and guidelines on what size mask to order.</p><p><strong>Conclusion: </strong>Our findings highlight the variability in providers' prescription practices for spacers. Future interventions should target provider education and addressing barriers to optimize asthma care.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-8"},"PeriodicalIF":1.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of IL-4RαR576 polymorphism on response to dupilumab in asthma, a genotype-stratified, randomized, placebo- controlled trial (IDEA trial): design, rationale, methods, strategies, and lessons learned.","authors":"Wanda Phipatanakul, Elliot Israel, David T Mauger, Susan J Kunselman, Patrice M Becker, Lisa Gagalis, Rachel L Dabek, Juliet Greenwood, Haejin Kim, Edward Zoratti, David C Kaelber, Mirna Ayache, Sunit Jariwala, Audreesh Banerjee, John Oppenheimer, Jonathan M Gaffin, Peggy S Lai, Tina M Banzon, Peter S Thorne, Hans C Oettgen, Pui Lee, Michael Lam, Talal A Chatila","doi":"10.1080/02770903.2026.2734972","DOIUrl":"10.1080/02770903.2026.2734972","url":null,"abstract":"<p><strong>Background/objective: </strong>Asthma is a heterogeneous chronic disease, disproportionately affecting racial and ethnic minorities, with persistence and severity influenced by both environmental and genetic factors. The IL-4RαR576 variant occurs more commonly in racially minoritized, and the genotype, independent of race, is associated with severe, exacerbation-prone asthma. IDEA (Investigating Dupilumab's Effect in Asthma by genotype) NCT03694158 is a multicenter, randomized, placebo-controlled trial designed to determine whether dupilumab, a monoclonal antibody that directly inhibits the IL-4 receptor, has differential efficacy according to IL-4Rα genotype, and to better understand genotype-specific asthma outcomes in adolescents and adults. At the time of this design and methods report, while enrollment is closed, the trial is ongoing and clinical outcome results are not yet available.</p><p><strong>Methods: </strong>IDEA enrolled participants aged 12 years and above with uncontrolled asthma. Eligible participants are genotyped for the IL-4RαR576 allele and stratified into wild-type, heterozygous, and homozygous groups. A total of 120 participants (goal of 48 wild-type, 48 heterozygous, 24 homozygous) are being randomized 1:1 to receive dupilumab or placebo in addition to guidelines-based therapy for 48 wk. The primary endpoint is reduction in asthma exacerbations. Digitalized strategies to address adherence in home administration of biologics are employed. Strategies to boost recruitment include new electronic health medical record tools, community advertising on public transportation and subway systems, and team members and sites in culturally attuned neighborhoods.</p><p><strong>Conclusions: </strong>IDEA evaluates response to a biologic by genotype. Results will inform future targeted therapies in genetically susceptible populations, with potential implications for reducing asthma disparities.Clinical Trials.gov NCT03694158.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-14"},"PeriodicalIF":1.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13648672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of social determinants of health with pediatric asthma hospitalization after treatment in the emergency department.","authors":"Michael D Johnson, Lawrence J Cook, Blake E Nielsen, Marion R Sills","doi":"10.1080/02770903.2026.2730878","DOIUrl":"10.1080/02770903.2026.2730878","url":null,"abstract":"<p><strong>Objective: </strong>Biomedical and non-biomedical factors influence outcomes for children with asthma exacerbations in emergency department (ED) settings. Modeling these factors may advance our understanding of drivers of health disparities, which will inform interventions to decrease them. Our aim is to quantify the association of Social Determinants of Health (SDoH) with hospitalization of children with acute asthma.</p><p><strong>Methods: </strong>This retrospective cross-sectional study examined all children 2-17 years old who visited a Pediatric Emergency Care Applied Research Network (PECARN) Registry site for acute asthma over four years. The primary outcome was hospitalization. Measures of clinical severity were age, sex, triage acuity, vital signs, and asthma history. Patient-level SDoH were race, ethnicity, and primary payer. Neighborhood-level SDoH was assessed by nationally-normed Child Opportunity Index (COI), based on zip code of the subject's address. Analysis included univariable and multivariable LASSO regression models. We compared area under the curve (AUC) between a model that included only clinical severity variables and models that added SDoH variables.</p><p><strong>Results: </strong>We included 65,706 visits from January 2017 to December 2020, of whom 26,160 (39.8%) were hospitalized. The AUC of the severity-only model was 0.798. The maximal AUC of models that included SDoH was 0.800. White non-Hispanic children had higher odds of hospitalization in all models.</p><p><strong>Conclusions: </strong>Addition of patient and neighborhood-level SDoH to a severity-only model did not increase predictive accuracy for hospitalization in children with asthma in a large multicenter cohort. Examination of care delivery and more detailed SDoH will be important to clarify why outcomes differ for children with asthma.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-11"},"PeriodicalIF":1.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148962907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revealing shared gene signatures and HIF-1α pathway in allergic rhinitis and asthma: a bioinformatics and experimental study.","authors":"Zhuiyue Wang, Jing Chen, Yuanyuan Zhang, Xiaoman Zhao, Shiping Shen, Xinguang Zhang, Wenbo Yao, Yazun Liu, Zheng Xue","doi":"10.1080/02770903.2026.2654630","DOIUrl":"10.1080/02770903.2026.2654630","url":null,"abstract":"<p><strong>Background: </strong>Allergic rhinitis (AR) and asthma (AS) are closely linked in both epidemiology and pathogenesis, though the mechanisms remain unclear. This study aims to identify shared gene signatures and molecular mechanisms in the combined allergic rhinitis and asthma syndrome (CARAS) and validate these findings in a murine model.</p><p><strong>Method: </strong>Gene expression data from the GEO database (GSE52804 for AR, GSE6858, and GSE41665 for AS) were analyzed. Differentially expressed genes (DEGs) were identified through bioinformatics. A protein-protein interaction (PPI) network was constructed using STRING, and hub genes were determined <i>via</i> Cytoscape. Gene Ontology (GO) and KEGG pathway analyses were conducted. A murine CARAS model was used to validate the role of the HIF-1α pathway.</p><p><strong>Results: </strong>We identified 56 DEGs, with IL6, Cxcl1, Ccl9, Cxcl2, Ccl20, Ccl11, and Cxcl5 as key hub genes. Key pathways influencing CARAS included viral protein interactions with cytokines, arachidonic acid metabolism, and HIF-1 signaling. CARAS mice exhibited substantial inflammation in nasal and lung tissues, accompanied by elevated levels of inflammatory cytokines and increased expression of NF-κB and HIF-1α proteins.</p><p><strong>Conclusions: </strong>IL-6 plays a critical role in CARAS, with the HIF-1α signaling pathway being significant in AR-AS interaction. These findings offer insights and potential biomarkers for future CARAS research and treatment.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1218-1232"},"PeriodicalIF":1.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147947668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-perceived mental health among Canadian adolescents and young adults with asthma: Insights from a national cross-sectional study.","authors":"Abdallah Alami, Julian Little, Alice Zwerling, Sami Aftab Abdul, Yue Chen, Daniel Krewski","doi":"10.1080/02770903.2026.2660321","DOIUrl":"10.1080/02770903.2026.2660321","url":null,"abstract":"<p><strong>Background: </strong>Asthma is a common chronic airway disease that often begins in adolescence and can persist into adulthood. While its physical health impacts are well documented, its broader psychosocial effects in youth remain underexplored. Emerging evidence suggests that females with asthma experience a greater mental-health burden than males, likely reflecting underlying biological and psychosocial differences. Few studies have examined the association using nationally representative data.</p><p><strong>Objective: </strong>To examine the association between asthma and poor self-perceived mental health among Canadian adolescents and young adults (AYA).</p><p><strong>Methods: </strong>We analyzed 20, 921 respondents aged 12-34 (drawn from 21,776 eligible participants) from the 2019-2020 Canadian Community Health Survey, a nationally representative cross-sectional survey. Descriptive analyses examined demographic, socioeconomic, behavioral, and health-related characteristics. Multivariable logistic regression models estimated adjusted odds ratios (aOR) for poor self-perceived mental health, controlling for key covariates. The interaction between asthma and sex was assessed on multiplicative and additive scales.</p><p><strong>Results: </strong>Poor mental health was more prevalent among those with asthma than those without. Asthma was associated with increased odds of poor mental health (aOR 1.72; 95% CI: 1.32-2.27). Sex-stratified analyses indicated a significant association in females but not in males. Measures of additive interaction indicated a synergistic effect between asthma and female sex.</p><p><strong>Conclusions: </strong>Female adolescents and young adults with asthma have higher odds of reporting poor self-perceived mental health compared to those without asthma, an association not observed in their male counterparts. The findings underscore the importance of incorporating routine mental health screening into asthma care and developing targeted psychosocial interventions for young females.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1275-1283"},"PeriodicalIF":1.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}